Trans 4 Hydroxyproline
Introduction
Background
Trans 4 hydroxyproline is a non-proteinogenic amino acid, meaning it is not directly incorporated into proteins during translation but is formed through post-translational modification. It is a derivative of the amino acid proline and is distinguished by the hydroxyl group at the 4th carbon in its trans configuration. This particular isomer is the predominant form found in biological systems.
Biological Basis
The primary biological significance of trans 4 hydroxyproline lies in its crucial role in the structure and stability of collagen, the most abundant protein in mammals. Collagen forms the major component of connective tissues such as skin, bone, cartilage, tendons, and ligaments. Trans 4 hydroxyproline is formed when specific proline residues within newly synthesized collagen chains undergo hydroxylation, a reaction catalyzed by a family of enzymes known as prolyl hydroxylases. This process requires vitamin C (ascorbic acid) as an essential cofactor. The presence of trans 4 hydroxyproline residues is vital for the formation of stable collagen triple helices, which are fundamental to the mechanical strength and integrity of connective tissues throughout the body.
Clinical Relevance
Due to its unique role in collagen, trans 4 hydroxyproline is clinically relevant as a biomarker for collagen metabolism and turnover. Elevated levels in biological fluids, particularly urine, can indicate increased collagen degradation, which may occur in various physiological and pathological conditions, including bone diseases (e.g., osteoporosis), inflammatory joint diseases, and certain cancers. Conversely, impaired formation of trans 4 hydroxyproline, often due to vitamin C deficiency, leads to the production of unstable collagen, manifesting as scurvy, a disease characterized by weakened connective tissues, fragility of blood vessels, and impaired wound healing.
Social Importance
The study of trans 4 hydroxyproline contributes to a broader understanding of human health, nutrition, and disease. Its utility as a biomarker offers insights into connective tissue health, enabling the monitoring of bone remodeling and the progression of diseases affecting collagen. Furthermore, its direct link to vitamin C highlights the importance of dietary intake for maintaining structural integrity of tissues. Research into the enzymes involved in its synthesis and degradation can lead to potential therapeutic targets for conditions characterized by abnormal collagen metabolism, thereby impacting public health strategies related to nutrition, aging, and chronic disease management.
Generalizability and Phenotypic Measurement Nuances
The findings for complex traits, such as trans 4 hydroxyproline, are often derived from cohorts predominantly composed of individuals of white European ancestry, which can restrict the generalizability of these associations to other ethnic or racial groups. [1] This demographic homogeneity, while controlling for population stratification, means that genetic variants and their effects observed may not be directly transferable or possess the same magnitude of effect in populations with different genetic backgrounds. Furthermore, potential biases such as survival bias can be introduced when DNA collection occurs in later examinations of a cohort, as individuals who are sicker or have passed away are excluded, potentially skewing the observed genetic associations. [1]
Measuring complex phenotypes presents its own set of challenges, as many biological traits do not follow a normal distribution. Extensive statistical transformations, such as log or Box-Cox power transformations, are frequently required to approximate normality for analysis, which can complicate the direct interpretation of effect sizes. [2] Additionally, specific cohort characteristics, such as the inclusion of individuals on particular medications (e.g., thyroxine replacement), can introduce specific biases that might influence the observed associations between genetic variants and the phenotype. [2]
Statistical Robustness and Replication Gaps
The moderate sample sizes often employed in initial genome-wide association studies (GWAS) can lead to insufficient statistical power, increasing the susceptibility to false negative findings. This limitation means that genuine genetic associations with smaller effect sizes may remain undetected. [1] The sheer number of statistical tests performed in a GWAS necessitates stringent correction for multiple comparisons, such as Bonferroni correction, which can further reduce the ability to detect true associations if their p-values do not meet the extremely low thresholds. [3]
A fundamental challenge in GWAS is the replication of findings across independent cohorts, which is crucial for validating initial associations and distinguishing true signals from false positives. Many reported associations fail to replicate, which can be attributed to differences in study design, population characteristics, or inadequate statistical power in replication cohorts. [1] Moreover, even when replication occurs within the same gene, different single nucleotide polymorphisms (SNPs) might show association across studies, suggesting either multiple causal variants or differences in linkage disequilibrium patterns across populations. [4]
Unaccounted Genetic and Environmental Influences
Current GWAS platforms assay only a subset of all possible genetic variants, meaning that significant genes or causal variants not present on the genotyping arrays, or not in strong linkage disequilibrium with genotyped SNPs, may be missed. This incomplete genomic coverage limits the comprehensive study of candidate genes and the discovery of novel loci. [5] Even for well-studied traits, a substantial proportion of the genetic variation remains unexplained, highlighting the phenomenon of "missing heritability." For instance, some studies indicate that known genetic variants account for only a fraction of the total heritability of a trait, leaving a large portion of the genetic architecture to be discovered. [3]
The influence of environmental factors, lifestyle choices, and gene-environment interactions can significantly confound genetic association analyses if not adequately accounted for. Studies often adjust for a range of covariates, including age, sex, BMI, and various comorbidities or medication uses, to mitigate these confounding effects. [2] However, the complex interplay between genetic predisposition and environmental exposures is not always fully captured, and unexplored gene-by-environment interactions may contribute to the unexplained phenotypic variance and impact the observed genetic effects. [6]
Variants
Genetic variations play a crucial role in influencing an individual's metabolic profile and overall health. Among these, single nucleotide polymorphisms (SNPs) within genes like SACM1L and PRODH2 can impact specific biochemical pathways, including those related to amino acid metabolism. Genome-wide association studies (GWAS) have demonstrated the power of identifying such genetic loci that influence metabolic traits, offering insights into underlying biological mechanisms. [7] Understanding these genetic associations can illuminate how subtle changes in DNA sequence contribute to variations in circulating metabolites, which are often indicative of physiological states. [8]
The gene SACM1L (Suppressor of ACT One Mutation 1-Like) encodes a phosphoinositide phosphatase, an enzyme critical for regulating lipid signaling pathways within cells. These pathways are involved in diverse cellular processes such as membrane trafficking, cell growth, and nutrient sensing. A variant like rs73060324 within or near SACM1L could potentially alter the gene's expression levels or the enzyme's activity, thereby influencing the balance of phosphoinositides. While SACM1L is not directly involved in proline metabolism, disruptions in general cellular signaling and membrane dynamics can indirectly affect processes like collagen synthesis and degradation, which are closely linked to trans 4 hydroxyproline levels. Altered cellular homeostasis due to SACM1L variations could therefore have downstream effects on the availability or turnover of trans 4 hydroxyproline, a key component of collagen. [2] These genetic influences on metabolic pathways are a common finding in large-scale genetic studies. [9]
In contrast, the PRODH2 gene (Proline Dehydrogenase 2, also known as P5CDH) plays a more direct role in amino acid metabolism, specifically in the catabolism of proline. PRODH2 encodes an enzyme that initiates the breakdown of proline, converting it into delta-1-pyrroline-5-carboxylate within the mitochondria. This process is essential for maintaining cellular energy balance and preventing the accumulation of toxic proline metabolites. A variant such as rs3761097 in PRODH2 could potentially affect the efficiency of this enzyme, leading to altered rates of proline degradation. Such an alteration could impact the overall pool of free proline available for various cellular functions, including its hydroxylation into trans 4 hydroxyproline during collagen synthesis. Therefore, variations in PRODH2 and their effects on proline metabolism are directly relevant to trans 4 hydroxyproline concentrations, as trans 4 hydroxyproline is derived from proline through enzymatic modification. Genetic variants influencing metabolic pathways, such as those impacting amino acid breakdown, often show significant associations with circulating metabolite levels. [7]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs73060324 | SACM1L | pneumonia, COVID-19 cerebrospinal fluid composition attribute, dimethylglycine measurement cerebrospinal fluid composition attribute, trans-4-hydroxyproline measurement |
| rs3761097 | PRODH2 | X-11315 measurement trans-4-hydroxyproline measurement blood metabolite level |
Lipid Metabolism and Homeostasis
The intricate balance of lipid metabolism is crucial for overall health, involving the synthesis, transport, and breakdown of various lipids, including cholesterol, triglycerides, and phospholipids. Key components in this process are lipoproteins, such as high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL), which facilitate lipid transport throughout the body. [10] Enzymes like hepatic lipase play a significant role in regulating plasma lipid levels, with genetic variations in its promoter region, such as the -514C->T polymorphism, influencing these concentrations. [11] Similarly, the activity of lipoprotein lipase, an enzyme critical for triglyceride hydrolysis, is modulated by factors like angiopoietin-like protein 4 (ANGPTL4), which can act as a potent hyperlipidemia-inducing factor and an inhibitor of lipoprotein lipase. [12]
Further regulation of lipid profiles involves other angiopoietin-like proteins, with ANGPTL3 influencing lipid metabolism and variations in ANGPTL4 being associated with reduced triglycerides and increased HDL levels. [13] The synthesis of fatty acids, a fundamental metabolic process, involves enzymes like acyl-malonyl acyl carrier protein-condensing enzyme. [14] Furthermore, the desaturation of fatty acids, particularly polyunsaturated fatty acids (PUFAs), is critical, with FADS1 (delta-5 desaturase) influencing the concentrations of various phosphatidylcholines and arachidonic acid. [7] Alterations in FADS1 activity, potentially due to polymorphisms, can shift the balance between eicosatrienoyl-CoA (C20:3) and arachidonyl-CoA (C20:4), thereby impacting the composition of glycerophospholipids. [7]
Genetic Regulation and Gene Expression
Genetic mechanisms exert substantial control over metabolic processes and cellular functions, with single nucleotide polymorphisms (SNPs) frequently influencing gene expression patterns and protein function. For instance, common SNPs in HMGCR, the gene encoding 3-hydroxy-3-methylglutaryl-CoA reductase, are associated with LDL-cholesterol levels and can affect the alternative splicing of exon 13. [15] Alternative splicing is a critical regulatory mechanism that allows a single gene to produce multiple protein isoforms, influencing protein function and contributing to human disease. [16] This process can be modulated by various factors, including antisense oligonucleotides, which can induce alternative splicing of messenger RNA, as seen with APOB. [17]
Beyond splicing, gene expression is also regulated by transcription factors and other genomic elements. SREBP-2 (Sterol Regulatory Element-Binding Protein 2) is a transcription factor that regulates genes involved in cholesterol and fatty acid synthesis, defining a link between isoprenoid and adenosylcobalamin metabolism. [18] Similarly, HNF4A (Hepatocyte Nuclear Factor 4 Alpha) is a critical regulator with gene associations tied to type 2 diabetes or altered beta-cell function. [19] Genome-wide association studies (GWAS) have identified numerous loci, including variations in MLXIPL and HNF4A, that influence plasma triglyceride levels, highlighting the polygenic nature of dyslipidemia. [19]
Cellular Signaling and Molecular Interactions
Cellular functions are orchestrated by intricate signaling pathways and specific molecular interactions between biomolecules. Proteins often interact through distinct structural motifs, such as the tetratricopeptide repeat, which mediates protein-protein interactions essential for diverse cellular processes. [20] Receptors play a pivotal role in cellular communication and uptake; for example, Tim4 has been identified as a phosphatidylserine receptor, important in cell recognition and efferocytosis. [21] Low-density lipoprotein receptor-related protein (LRP) interacts with MafB, a transcription factor involved in hindbrain development, showcasing receptor involvement in developmental processes. [22]
Beyond direct interactions, proteins can also participate in signaling cascades that regulate cellular responses. The human tribbles protein family, for instance, controls mitogen-activated protein kinase (MAPK) cascades, which are fundamental in regulating cell growth, differentiation, and stress responses. [23] Hormones, such as thyroxine (T4) and tri-iodothyronine (T3), are critical signaling molecules that influence metabolism and are often used in replacement therapies for thyroid conditions. [24] Structural components like Neurocan, a brain chondroitin sulfate proteoglycan, also contribute to the extracellular matrix, influencing cell interactions and tissue organization. [25]
Pathophysiological Consequences and Systemic Effects
Disruptions in molecular and cellular pathways can lead to various pathophysiological conditions, affecting multiple tissues and organs. Dyslipidemia, characterized by abnormal lipid levels, is a significant risk factor for coronary artery disease, with numerous genetic loci contributing to its polygenic nature. [19] Conditions like hypertriglyceridemia can arise from mechanisms such as diminished VLDL fractional catabolic rate, often associated with increased APOCIII and reduced ApoE on lipoprotein particles. [26] Notably, a null mutation in human APOC3 has been shown to confer a favorable plasma lipid profile and offer apparent cardioprotection. [27]
Metabolic syndrome pathways, involving genes like LEPR, HNF1A, IL6R, and GCKR, have been linked to systemic inflammation, as evidenced by associations with plasma C-reactive protein levels. [28] Beyond lipid disorders, genetic variations can contribute to other conditions; for example, a common nonsynonymous variant in GLUT9 is associated with serum uric acid levels, influencing uric acid excretion and the risk of gout. [29] Moreover, substitutions at key protein positions, such as valine to isoleucine changes, can alter protein structure and function, leading to clinically relevant phenotypes in disorders like sickle cell disease, Alzheimer's disease, and rheumatoid arthritis. [30]
References
[1] Benjamin, E. J., et al. "Genome-wide association with select biomarker traits in the Framingham Heart Study." BMC Med Genet, vol. 8, 2007, p. 64.
[2] Melzer D et al. A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet. 2008;4(5):e1000078.
[3] Benyamin, B., et al. "Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels." Am J Hum Genet, vol. 84, no. 1, 2009, pp. 60-65.
[4] Sabatti, C., et al. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nat Genet, vol. 40, no. 12, 2008, pp. 1394-1402.
[5] Yang, Q., et al. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Med Genet, vol. 8, 2007, p. 65.
[6] Dehghan, A., et al. "Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study." Lancet, vol. 372, no. 9654, 2008, pp. 1959-1965.
[7] Gieger C et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet. 2008;4(11):e1000282.
[8] Wallace C et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet. 2008;82(1):139-49.
[9] Pare G et al. Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet. 2008;4(7):e1000118.
[10] Havel, R. J., and J. P. Kane. "Structure and Metabolism of Plasma Lipoproteins." McGraw-Hill, 2005.
[11] Isaacs, A., et al. "The - 514C->T hepatic lipase promoter region polymorphism and plasma lipids: a meta-analysis." J. Clin. Endocrinol. Metab., vol. 89, 2004, pp. 3858-3863.
[12] Yoshida, K., et al. "Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase." J. Lipid Res., vol. 43, 2002, pp. 1770-1772.
[13] Koishi, R., et al. "Angptl3 regulates lipid metabolism in mice." Nat Genet, vol. 30, 2002, pp. 151-157.
[14] Toomey, R. E., and S. J. Wakil. "Studies on the mechanism of fatty acid synthesis. XVI. Preparation and general properties of acyl-malonyl acyl carrier protein-condensing enzyme from Escherichia coli." J. Biol. Chem., vol. 241, 1966, pp. 1159-1165.
[15] Burkhardt, R., et al. "Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13." Arterioscler Thromb Vasc Biol, vol. 28, no. 11, 2008, pp. 2071-2079.
[16] Matlin, A. J., et al. "Understanding alternative splicing: towards a cellular code." Nat Rev Mol Cell Biol, vol. 6, 2005, pp. 386-398.
[17] Khoo, B., et al. "Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB." BMC Mol Biol, vol. 8, 2007, p. 3.
[18] Murphy, C., et al. "Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism." Biochem Biophys Res Commun, vol. 355, 2007, pp. 359-364.
[19] Kathiresan, S., et al. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nat Genet, vol. 41, no. 5, 2009, pp. 565-571.
[20] Blatch, G. L., and M. Lassle. "The tetratricopeptide repeat: a structural motif mediating protein-protein interactions." Bioessays, vol. 21, 1999, pp. 932-939.
[21] Miyanishi, M., et al. "Identification of Tim4 as a phosphatidylserine receptor." Nature, vol. 450, 2007, pp. 435-439.
[22] Petersen, H. H., et al. "Low-density lipoprotein receptor-related protein interacts with MafB, a regulator of hindbrain development." FEBS Lett, vol. 565, 2004, pp. 23-27.
[23] Kiss-Toth, E., et al. "Human tribbles, a protein family controlling mitogen-activated protein kinase cascades." J Biol Chem, vol. 279, 2004, pp. 42703-42708.
[24] Saravanan, P., et al. "Partial substitution of thyroxine (T4) with tri-iodothyronine in patients on T4 replacement therapy: results of a large community-based randomized controlled trial." J Clin Endocrinol Metab, vol. 90, 2005, pp. 805-812.
[25] Rauch, U., et al. "Neurocan: a brain chondroitin sulfate proteoglycan." Cell Mol Life Sci, vol. 58, 2001, pp. 1842-1856.
[26] Aalto-Setala, K., et al. "Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles." J. Clin. Invest., vol. 90, 1992, pp. 1889-1900.
[27] Pollin, T. I., et al. "A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection." Science, vol. 322, no. 5904, 2008, pp. 1702-1705.
[28] Ridker, P. M., et al. "Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study." Am J Hum Genet, vol. 82, no. 5, 2008, pp. 1185-1192.
[29] McArdle, P. F., et al. "Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order amish." Arthritis Rheum, 2008.
[30] Monplaisir, N., et al. "Hemoglobin S Antilles: a variant with lower solubility than hemoglobin S and producing sickle cell disease in heterozygotes." Proc Natl Acad Sci U S A, vol. 83, no. 24, 1986, pp. 9363-9367.